Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HAMS-AB
- Development stage
- Phase 1
- Lead developer
- Indiana University
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
HAMS-AB (acetylated and butyrylated high amylose maize starch) is a prebiotic dietary supplement being developed by Indiana University for the treatment of newly diagnosed type 1 diabetes mellitus. It consists of high amylose maize starch that has been chemically modified through acetylation and butyrylation. Upon reaching the colon, HAMS-AB is fermented by gut microbiota, leading to the increased production of short-chain fatty acids (SCFAs), specifically acetate and butyrate. These SCFAs are thought to modulate the immune system, reduce inflammation, and improve gut barrier integrity, thereby potentially preserving beta-cell function and improving glycemic control in patients with type 1 diabetes. The intervention is typically administered as a powder mixed with food.
- Other names
- Acetylated and Butyrylated High Amylose Maize Starch
Beyond the preview
Go deeper on HAMS-AB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HAMS-AB.